The risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Rituximab. Metamizole may increase the anticoagulant activities of Ardeparin. The risk or severity of myelosuppression can be increased when Metamizole is combined with Ixabepilone. The risk or severity of adverse effects can be increased when Metamizole is combined with Equilin. The risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast. The risk or severity of adverse effects can be increased when Metamizole is combined with Parthenolide. The risk or severity of myelosuppression can be increased when Metamizole is combined with Trastuzumab emtansine. Metamizole may decrease the excretion rate of GPX-150 which could result in a higher serum level. Metamizole may decrease the antihypertensive activities of Carteolol. Metamizole may decrease the antihypertensive activities of Befunolol. Metamizole may increase the neuroexcitatory activities of Sparfloxacin. The risk or severity of adverse effects can be increased when Metamizole is combined with Tinoridine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Mechlorethamine. The risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate. Metamizole may increase the anticoagulant activities of Certoparin. The risk or severity of adverse effects can be increased when Metamizole is combined with Indobufen. Metamizole may increase the anticoagulant activities of Gabexate. Metamizole may increase the anticoagulant activities of Warfarin. Metamizole may increase the neuroexcitatory activities of Rosoxacin. The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole. Metamizole may increase the anticoagulant activities of Danaparoid. The risk or severity of adverse effects can be increased when Leflunomide is combined with Metamizole. The therapeutic efficacy of Dinoprost can be decreased when used in combination with Metamizole. Metamizole may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Metamizole may increase the anticoagulant activities of Troxerutin. The risk or severity of adverse effects can be increased when Moexipril is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Obinutuzumab. The risk or severity of myelosuppression can be increased when Metamizole is combined with Palbociclib. The risk or severity of myelosuppression can be increased when Metamizole is combined with Tioguanine. The risk or severity of adverse effects can be increased when Metamizole is combined with Halcinonide. The risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate. The risk or severity of adverse effects can be increased when Metamizole is combined with Flumethasone. Metamizole may decrease the excretion rate of Geneticin which could result in a higher serum level. The risk or severity of myelosuppression can be increased when Metamizole is combined with Vinorelbine. Metamizole may increase the anticoagulant activities of Lepirudin. The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Carmustine. The risk or severity of adverse effects can be increased when Metamizole is combined with Prednisone. Metamizole may increase the neuroexcitatory activities of Trovafloxacin. The risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinolone Acetonide. The risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol. The risk or severity of adverse effects can be increased when Metamizole is combined with Atamestane. The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Metamizole. The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Andrographolide. Metamizole may increase the anticoagulant activities of Ethyl biscoumacetate. Metamizole may increase the anticoagulant activities of Nadroparin. The risk or severity of adverse effects can be increased when Masoprocol is combined with Metamizole. Metamizole may increase the anticoagulant activities of Citric Acid. The risk or severity of adverse effects can be increased when Omapatrilat is combined with Metamizole. The therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Difluprednate. The risk or severity of adverse effects can be increased when Metamizole is combined with Propacetamol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Temsirolimus. The risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid. The risk or severity of adverse effects can be increased when Metamizole is combined with Tiludronic acid. The risk or severity of adverse effects can be increased when Metamizole is combined with Loteprednol. Metamizole may decrease the excretion rate of Netilmicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Perindopril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Docetaxel. The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Apremilast. The risk or severity of myelosuppression can be increased when Metamizole is combined with Linezolid. Metamizole may increase the anticoagulant activities of Edetic Acid. The risk or severity of myelosuppression can be increased when Metamizole is combined with Cytarabine. Metamizole may decrease the antihypertensive activities of Oxprenolol. Metamizole may increase the anticoagulant activities of Protein S human. Metamizole may decrease the antihypertensive activities of Levobunolol. The risk or severity of adverse effects can be increased when Metamizole is combined with Difluocortolone. The risk or severity of adverse effects can be increased when Metamizole is combined with Bucillamine. The risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant. The risk or severity of adverse effects can be increased when Metamizole is combined with Alclometasone. Metamizole may increase the anticoagulant activities of Dalteparin. Metamizole may decrease the antihypertensive activities of Bupranolol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Blinatumomab. The risk or severity of myelosuppression can be increased when Metamizole is combined with Decitabine. Metamizole may increase the neuroexcitatory activities of Grepafloxacin. The risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole. Metamizole may increase the neuroexcitatory activities of Pazufloxacin. The risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone. Metamizole may decrease the antihypertensive activities of Arotinolol. Metamizole may decrease the antihypertensive activities of Spironolactone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Irinotecan. The risk or severity of myelosuppression can be increased when Metamizole is combined with Bortezomib. The risk or severity of adverse effects can be increased when Metamizole is combined with Cortisone acetate. The risk or severity of adverse effects can be increased when Naproxen is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Dinutuximab. The risk or severity of myelosuppression can be increased when Metamizole is combined with Aldesleukin. Metamizole may decrease the excretion rate of Pirarubicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with Epirizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Fluocortolone. The risk or severity of adverse effects can be increased when Imidapril is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Pentostatin. Colestipol can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Metamizole is combined with Serrapeptase. The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen. The risk or severity of adverse effects can be increased when Valdecoxib is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib. The risk or severity of adverse effects can be increased when Talniflumate is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Talinolol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Ponatinib. The risk or severity of adverse effects can be increased when Diflunisal is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Cabazitaxel. Metamizole may increase the anticoagulant activities of Dabigatran etexilate. The risk or severity of adverse effects can be increased when Spirapril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Prednicarbate. Metamizole may increase the anticoagulant activities of Ximelagatran. The risk or severity of myelosuppression can be increased when Metamizole is combined with Mercaptopurine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Hydroxyurea. Metamizole may decrease the antihypertensive activities of Bopindolol. Metamizole may decrease the antihypertensive activities of Bucindolol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2a. Metamizole may increase the anticoagulant activities of Dicoumarol. The risk or severity of adverse effects can be increased when Trandolapril is combined with Metamizole. The risk or severity of adverse effects can be increased when Fosinopril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Budesonide. The risk or severity of adverse effects can be increased when Metamizole is combined with Cortexolone 17α-propionate. Metamizole may increase the nephrotoxic activities of Balsalazide. The risk or severity of myelosuppression can be increased when Metamizole is combined with Tofacitinib. The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Topotecan. The therapeutic efficacy of Limaprost can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Metamizole. Metamizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Metamizole may increase the nephrotoxic activities of Mesalazine. The risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.